Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

04/20/2012 | 08:16pm US/Eastern
Recommend:
0

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

XIANYANG, China, April 20, 2012/PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in Chinafor a variety of diseases and conditions, today announced that it has received written notification from the Nasdaq Listing Qualifications department that it has regained compliance with the minimum bid price requirement of $1.00per share for continued listing of its common stock on The NASDAQ Global Market set forth in Nasdaq Listing Rule 5450(a)(1), as its common shares achieved a closing bid price of $1.00or more for 10 consecutive business days prior to the compliance deadline of April 23, 2012and this matter is now closed.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to maintain its ongoing compliance with the Nasdaq continued listing requirements, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:




BioStar Pharmaceuticals, Inc. 

The Equity Group, Inc.

Zack Pan, CFO 

Lena Cati

Tel: 405-996-8829 

Tel: 212 836-9611

Email: zpan@aoxing-group.com

Email: lcati@equityny.com

SOURCE Biostar Pharmaceuticals, Inc.

distributed by
Recommend :
0
React to this article
Latest news
Date Title
2m ago TAKEDA PHARMACEUTICAL : invests in Vaccine Safe Co., a subsidiary wholly-owned by Alfresa Corporation
2m ago PLUS500 : Notice of Q3 Trading Update
3m ago TUI TRAVEL : Confirms Full-Year Profit Growth At Top End Of Guidance
4m ago BIOFRONTERA : Ad hoc: Biofrontera AG: Clinical program for US approval of Ameluz® approaches completion: Studies confirm excellent efficacy and safety
5m ago Cherokee Nation Calendar of Events for October
7m ago Renault aims to reclaim lost ground with minivan turned SUV
7m ago ELECTROCOMPONENTS : Trading Statement
7m ago GAMESA CORPORACION TECNOLOGICA : The Company submits the signature of an agreement for the supply of wind turbine generators in Brazil, with a total capacity of 220 MW
7m ago GAMESA CORPORACION TECNOLOGICA : signs new contract for the supply of 110 of its G114-2.0 MW turbines in Brazil
7m ago UTILICO INVESTMENTS : Director Shareholding - P Burrows 1 Oct 2014
Latest news
Advertisement
Hot News 
BLINKX : Analysts call for Blinkx to sell up after second profit warning hits
YOUGOV : Optimism in London ... steady as we go or has it stalled?
NUMIS : boss hails old fashioned advantage over hi-tech big banks
CRODA : *deutsche bank cuts croda price target to 2200 pence - 'hold'
ALLETE : Minnesota Power : Applauds Essar Steel Minnesota's Successful Refinancing as Positive News for Region
Most Read News
1d ago JANUS CAPITAL : Pimco Total Return Fund posts record $23.5 billion net outflow in September
1d ago JPMORGAN CHASE : to Present at the Bank of America Merrill Lynch Banking & Financial Services Conference
1d ago TOTAL SYSTEM SERVICES : Pimco Total Return Fund posts record $23.5 billion net outflow in September
1d ago CANADIAN PACIFIC RAILWAY : CP Rail looks to boost revenue to C$10 billion in 2018
2h ago TESLA MOTORS : Musk says 'about time to unveil the D and something else'
Most recommended articles
6m ago Renault aims to reclaim lost ground with minivan turned SUV
8m ago As PIMCO bleeds assets, Gross shows risk of star culture
9m agoDJAREVA : to Supply Nuclear Fuel for EDF's French Reactors in 2015-2021
16m ago INSIGHT - TESCO'S 250-MILLION-POUND BLACK HOLE : Who was minding the shop?
17m ago BILL GROSS : As PIMCO bleeds assets, Gross shows risk of star culture
Dynamic quotes  
ON
| OFF